Frazier Healthcare Partners Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 33
- Investments
- 384
- Portfolio
- 49
- Exits
- 176
Frazier Healthcare Partners General Information
Description
Founded in 1991, Frazier Healthcare Partners is a provider of growth and venture capital to healthcare companies. The firm's Growth Buyout team invests in healthcare and pharmaceutical services, medical products, and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. It is based in Seattle, Washington.
Contact Information
Investor Status
Actively Seeking New Investments
Trade Association
National Venture Capital Association (NVCA)
Primary Investor Type
Venture Capital
Other Investor Types
Growth/Expansion
PE/Buyout
Primary Office
- Two Union Square, 601 Union Street
- Suite 3200
- Seattle, WA 98101
- United States
+1 (206) 000-0000
Frazier Healthcare Partners Investments (384)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Imago BioSciences | 19-Nov-2020 | Later Stage VC | 0000 | Drug Discovery | Clinical Trials - Phase 3 | |
| 00000000 | 11-Nov-2020 | 00000 00000 | 0000 | Drug Delivery | Startup | 000000 00000 00.0 |
| 00000000 | 02-Oct-2020 | 0000000000 | Diagnostic Equipment | Generating Revenue | 000 0000000 | |
| 00000 000000 00000 | 22-Sep-2020 | 0000000000 | Pharmaceuticals | Generating Revenue | 000000 00000 00 | |
| 000 00000000000 | 27-Jul-2020 | 00000 00000 | 000.00 | Drug Discovery | Startup | 0000000 00000 |
| 00000000 | 30-Jun-2020 | 00000 00000 | 00000 | Drug Discovery | Pre-Clinical Trials | |
| 000000 | 26-Jun-2020 | 0000 | 00000 | Drug Discovery | Generating Revenue/Not Profitable | |
| 0000000 00000000 | 27-May-2020 | 0000 | 00.00 | Therapeutic Devices | Generating Revenue/Not Profitable | |
| Lengo Therapeutics | 12-May-2020 | Early Stage VC | 0000 | Drug Discovery | Generating Revenue | 000000 00000 00.0 |
| Dascena | 30-Apr-2020 | Later Stage VC | 0000 | Outcome Management (Healthcare) | Generating Revenue | 00000 00000 00 |
Frazier Healthcare Partners Exits (174)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Iterum Therapeutics | 26-Oct-2020 | Public Investment 2nd Offering | 000.00 |
| 000000 00000000000 | 16-Oct-2020 | 000 | 0000 |
| 000 000000 0000000 | 20-Aug-2020 | 0000000000 | |
| 00000000 | 07-Aug-2020 | 000 | 00000 |
| 0000000 | 12-Jun-2020 | 000 | 00000 |
| 0000000 000 | 28-Feb-2020 | 000 | 00000 |
| 0000000 0000000000 | 31-Jan-2020 | 000 | 00000 |
| 0000000 | 13-Jan-2020 | 000000 0000000000 | 000.00 |
| Aradigm | 30-Oct-2019 | Bankruptcy: Admin/Reorg | |
| Phathom Pharmaceuticals | 25-Oct-2019 | IPO | 00000 |
Frazier Healthcare Partners Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialFrazier Healthcare Partners Team (118)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Thomas Hodge JD | Senior Advisor | Seattle, WA | |||
| Steve Bailey | Chief Financial Officer & Partner | Seattle, WA | |||
| Patrick Heron | Managing General Partner, Life Sciences | 00 | 0 | 0 | Menlo Park, CA |
| Nader Naini | Managing Partner | 00 | 0 | 0 | Seattle, WA |
| Brian Morfitt | General Partner | 00 | 0 | 0 | Seattle, WA |
Frazier Healthcare Partners Co-Investors (142)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| OrbiMed | 6 | 0 | 0 |
|
|
| Nan Fung Life Sciences | 0 | 0 |
|
|
|
| Novo Holdings | 0 | 0 | 0 |
|
|
| Vivo Capital | 0 | 0 | 0 |
|
|
| Longitude Capital | 0 | 0 | 0 |
|
|